Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. Heart rhythm O2 Ugowe, F. E., Hellkamp, A. S., Wang, A., Becker, R. C., Berkowitz, S. D., Breithardt, G., Fox, K. A., Halperin, J. L., Hankey, G. J., Mahaffey, K. W., Nessel, C. C., Singer, D. E., Patel, M. R., Piccini, J. P., of the ROCKET AF Steering Committee and Investigators 2021; 2 (3): 215-222


Background: Insulin use may be a better predictor of stroke risk and morbidity and mortality than diabetes in patients with atrial fibrillation (AF).Objectives: Determine if the increased risk of stroke observed in patients with AF and diabetes is restricted to those treated with insulin.Methods: We analyzed the association between diabetes and treatment and the occurrence of stroke/systemic embolism, myocardial infarction (MI), all-cause death, vascular death, composite outcomes, and bleeding risk in the ROCKET AF trial.Results: In a cohort of 14,264 patients, there were 40.3% (n= 5746) with diabetes, 5.9% (n = 842) on insulin, 18.9% (n = 2697) on oral medications, and 11.9% (n = 1703) diet-controlled. Compared to those without diabetes, patients with non-insulin-treated diabetes had increased risks of stroke (hazard ratio [HR] 1.33, 95% confidence interval [CI] 1.06-1.68), MI (HR 1.64, 95% CI 1.17-2.30), all-cause death (HR 1.26, 95% CI 1.08-1.46), vascular death (HR 1.33, 95% CI 1.11-1.60), and composite outcomes (HR 1.37, 95% CI 1.18-1.157). Patients with insulin-treated diabetes had a significantly higher risk of MI (HR 2.31, 95% CI 1.33-4.01) and composite outcomes (HR 1.57, 95% CI 1.19-2.08) compared to those without diabetes. There were no significant differences between insulin-treated and non-insulin-treated diabetes for any outcome.Conclusion: Among patients with AF and diabetes, there were no significant differences in outcomes in insulin-treated diabetes compared to non-insulin-treated diabetes.

View details for DOI 10.1016/j.hroo.2021.04.001

View details for PubMedID 34337571